About: Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. is headquartered in New York, New York.
Sector: Healthcare
Industry: Biotechnology
Latest price: $30.16 (-5.99%)
DFTX NASDAQ Definium Therapeutics, Inc.
Definium Therapeutics, Inc. share price
DFTX price activity
Last Price
$30.160
Change (24hr)
-1.92 USD (5.99%)
Volume
1.13M
Volume (4w avg)
-
Open
$31.47
Day Range
$30.05 - $32.43
Previous Close
$32.08
Last Trade
16 Nov, 9:00 pm GMT+0
Delayed
16 Nov, 9:00 pm GMT+0
DFTX price performance
Delayed
16 Nov, 9:00 pm GMT+0
DFTX details
DFTX Market Signals